Serum Paraoxonase-1 and Atherosclerotic Cardiovascular Disease
Küçük Resim Yok
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Czech Soc Cardiology & Czech Soc Cardiovascular Surgery
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Due to where paraoxonase-1 (PON-1)'s hydrophobic lipid domain is located, high-density lipoprotein (HDL) protects low-density lipoprotein (LDL) and the cell membranes on the outside from oxidation. It doesn't stop the formation of conjugated dienes, but it changes the products of lipid peroxidation into harmless carboxylic acids instead of aldehydes that could link to apolipoprotein B. Serum PON-1 inversely affects new events in diabetes and atherosclerotic cardiovascular disease (ASCVD). Diabetes, dyslipidemia, and inflammation decrease PON-1 activity. Human PON-1 gene ablation or overexpression in animals enhances or reduces atherosclerosis susceptibility. Unlike AII, serum amyloid A, and myeloperoxidase, apolipoprotein AI and lecithin : cholesterol acyl transferase boost PON-1 antioxidant activity. Diet and pre-existing lipid-modifying drugs may impact PON-1 activity, but specific PON-1-raising therapy is required.
Açıklama
Anahtar Kelimeler
Atherosclerotic cardiovascular, disease, High-density lipoprotein, Paraoxonase-1
Kaynak
Cor Et Vasa
WoS Q Değeri
Q4
Scopus Q Değeri
Q4
Cilt
66
Sayı
6
